한국어
English
日本語
中文(简体)Imydu Injection (Tremelimumab)
300mg
Injections · Prescription medication
AstraZeneca Korea Co., Ltd.
Tremelimumab is an anticancer immunomodulator that activates T cells in the immune system to help attack cancer cells.
MFDS ingredient code M265034
Tremelimumab is a monoclonal antibody belonging to the immune checkpoint inhibitor class. It is used to assist the immune system's T cells in recognizing and attacking cancer cells for cancer treatment. It is primarily used to enhance immune responses in certain types of cancer.
Tremelimumab works by blocking the CTLA-4 protein on the surface of T cells, allowing T cells to be activated without suppression. As a result, the immune system can recognize and attack cancer cells more effectively, leading to the suppression of cancer cell growth.
Approved uses differ by product. Check each product's information for its actual use.
Tremelimumab is one of the immune checkpoint inhibitors that target CTLA-4, and it has a different mechanism of action compared to other immune checkpoint inhibitors that target PD-1 or PD-L1. This allows it to be used alone or in combination therapies for certain types of cancer, with differences in how immune responses are regulated.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.